Parkinson's Disease clinical trial intelligence

Evaluation of [18F]MC225-PET to Measure P-glycoprotein Function in Neurodegenerative Disease

Evaluation of [18F]MC225-PET to Measure P-glycoprotein Function in Neurodegenerative Disease is a PHASE1 clinical asset sponsored by University Medical Center Groningen in Neurodegenerative Diseases, Alzheimer Disease, Parkinson Disease, Mild Cognitive Impairment. SEO and diligence focus: [18F]MC225, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Parkinson Disease

NYSCF Scientific Discovery Biobank

NYSCF Scientific Discovery Biobank is a registry-stage clinical asset sponsored by New York Stem Cell Foundation Research Institute in ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder. SEO and diligence focus: Biological Sample Collection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Parkinson Disease

The Brain Eye Amyloid Memory (BEAM) Study: Validation of Ocular Measures as Potential Biomarkers for Early Detection of Brain Amyloid and Neurodegeneration

The BEAM study, sponsored by Sunnybrook Health Sciences Centre, aims to validate non-invasive ocular measurements as biomarkers for early detection of neurodegenerative diseases, including Alzheimer's Disease and Mild Cognitive Impairment. This study is positioned in a growing market focused on early diagnostics for dementia, which is increasingly critical as the global aging population expands. The findings could enhance the competitive landscape for diagnostic tools in neurodegeneration, potentially leading to partnerships or licensing opportunities with companies specializing in ocular imaging and neurodegenerative diagnostics. The study's collaboration with GE Healthcare indicates a strategic alignment with industry leaders, enhancing its commercial viability.

Matched by conditions: Parkinson's Disease

A Phase 2, Randomized, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) And Parkinson's Disease (PD) Patients

The trial, sponsored by Istanbul Medipol University Hospital, explores a novel combination of metabolic cofactors aimed at improving cognitive and motor functions in AD and PD patients. Given the increasing prevalence of these neurodegenerative diseases, successful outcomes could position this therapy favorably in a competitive market that includes established treatments and emerging therapies. The combination approach may offer a differentiated product profile, appealing to both patients and healthcare providers. Further, the collaboration with industry partners like ScandiBio Therapeutics AB suggests potential for commercialization and broader market access. Diligence should focus on the safety profile and efficacy data to assess market entry viability and reimbursement potential.

Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Complications

Cerevance's CVN424 is currently undergoing a Phase 3 clinical trial aimed at addressing motor complications in Parkinson's disease, a significant unmet medical need in a market projected to grow substantially due to increasing prevalence. The trial's design, being randomized and placebo-controlled, positions CVN424 competitively against existing therapies. Given the estimated enrollment of 330 participants and the potential for an open-label extension study, successful outcomes could lead to a strong market entry. However, the competitive landscape includes established therapies and emerging candidates, necessitating robust efficacy and safety data to differentiate CVN424. Additionally, the trial's stringent eligibility criteria may limit patient recruitment, impacting timelines and market entry.

Matched by conditions: Parkinson Disease

Using Behavioral Economics and Implementation Science to Advance the Use of Genomic Medicine Utilizing an EHR Infrastructure Across a Diverse Health System

The University of Pennsylvania's clinical trial aims to innovate the implementation of genomic medicine by utilizing behavioral economics and advanced EHR systems. This approach targets a growing market for genetic testing, particularly as indications expand and the clinical utility of genetic results becomes increasingly recognized. The trial's focus on non-geneticist clinician and patient nudges positions it uniquely within the competitive landscape, potentially leading to improved patient outcomes and increased adoption of genetic testing across diverse health systems. The findings could influence reimbursement strategies and policy-making in genomic medicine, presenting opportunities for partnerships with EHR vendors and genetic testing laboratories.

Matched by conditions: Parkinson Disease